At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 382 enrolled
Drug / intervention
Fingolimoddrug
Likely dose
Fingolimod 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]
In Brief
A Phase 4 clinical trial evaluating Fingolimod for Relapsing Multiple Sclerosis. Completed, enrolled 382 participants across 66 sites.
Detailed Summary
A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Multiple Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionMar 2019
Study CompletionJun 2019
TodayJul 2026
First PostedAug 22, 2017
Enrollment StartSep 19, 2017
Primary CompletionMar 5, 2019
Study CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.9 years ago
Interventions
Fingolimoddrug
Commercially available 0.5mg hard capsules, taken orally once per day